SIV-specific antibodies protect against inflammasome-driven encephalitis in untreated macaques

Natalie J Castell1, Celina M Abreu1, Erin N Shirk1

  • 1Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Cell Reports
|October 9, 2024
PubMed

Insights

Simian immunodeficiency virus encephalitis (SIVE) in macaques involves myeloid brain lesions and inflammasome activation. Poor immunoglobulin G (IgG) response predicts SIVE, offering insights into viral encephalitis pathogenesis.

Area of Science:

  • Neuroscience
  • Immunology
  • Virology

Background:

  • Viral encephalitis poses a significant public health challenge with limited therapeutic and diagnostic tools.
  • Simian immunodeficiency virus (SIV)-infected macaques serve as a critical model for studying human immunodeficiency virus (HIV) and its neurological complications.
  • A substantial proportion of untreated pigtail macaques develop SIV encephalitis (SIVE), mirroring aspects of HIV neuropathogenesis.

Purpose of the Study:

  • To investigate immune responses in plasma, cerebrospinal fluid (CSF), and brain tissue of SIV-infected macaques.
  • To identify immune correlates associated with the development of SIV encephalitis (SIVE) pathology.
  • To understand the mechanisms underlying the heterogeneous outcomes observed in viral encephalitis.

Main Methods:

  • Analysis of immune markers in plasma, CSF, and brain tissue from SIV-infected macaques.
  • Assessment of inflammasome activation using interleukin (IL)-1β, IL-18, and ASC.
  • Quantification of chemokines (MCP-1, MIP-1α) and cytokines (TNF-α).
  • Evaluation of SIV-specific immunoglobulin G (IgG) seroconversion over time.

Main Results:

  • Macaques with SIVE exhibited myeloid-dominant brain lesions characterized by inflammasome activation (IL-1β, IL-18, ASC).
  • Elevated levels of MCP-1, MIP-1α, and TNF-α were observed in macaques with SIVE.
  • SIV-specific IgG in plasma and CSF predicted SIVE development as early as 21 days post-inoculation.
  • Animals developing SIVE showed minimal seroconversion even after 3 months.

Conclusions:

  • A dichotomy exists in immune responses, with a failure to mount robust IgG responses correlating with SIVE development.
  • These findings provide crucial insights into the pathogenesis of SIV encephalitis and the varied clinical outcomes in viral encephalitis.
  • Understanding these immune dysregulations can inform the development of novel diagnostic and therapeutic strategies for viral encephalitis.